| BHOF in the News, Osteoporosis in the News

To reduce the risk of hip and vertebral fractures in women with osteoporosis, physicians should treat them with the bisphosphonates risedronate, alendronate, or zoledronic acid, or alternatively with the biologic agent denosumab. This strong recommendation appears in revised guidelines from the American College of Physicians (ACP) for the prevention of fractures in men and women with osteoporosis and low bone density.

Read the full article here.